US Patent

US8547248 — Implantable zero-wire communications system

Method of Use · Assigned to Proteus Digital Health Inc · Expires 2030-12-18 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an implantable system that enables wireless communication between medical devices using a unique format and quasi-electrostatic signal transmission.

USPTO Abstract

The present invention provides implantable systems that communicate wirelessly with each other using a unique format that enables devices configurations and applications heretofore not possible. Embodiments of the present invention provide communication apparatuses and methods for exchanging information with implantable medical devices. In some embodiments, two implantable devices communicate with each other using quasi-electrostatic signal transmission in a long wavelength/low frequency electromagnetic band, with the patient's body acting as a conductive medium.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2167 — Abilify
U-2167 — Abilify
U-2167 — Abilify
U-2167 — Abilify
U-2167 — Abilify
U-2167 — Abilify

Patent Metadata

Patent number
US8547248
Jurisdiction
US
Classification
Method of Use
Expires
2030-12-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Proteus Digital Health Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.